Post Date:Jul-27-23
Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Author: AcceGen R&D TeamDate Published: 27-Jul-23
- Authors: Jeff Hsu, Colin Chong, Jeffrey Serrill, Levina Goon, Joan Balayan, Eric N Johnson, Grachelle Lorenzana, Sharon Wu, Kevin G Leong, Theodore J Yun, Yong Wang, Faming Jiang, Lynne Bannen, Peter Lamb, Wei Xu, Peiwen Yu
- Journal: Molecular cancer therapeutics
- DOI: 10.1158/1535-7163.MCT-22-0262
- Cited AcceGen Product/Service: MDA-MB-231
Copyright - Unless otherwise stated all contents of this website are AcceGen™ All Rights Reserved – Full details of the use of materials on this site please refer to AcceGen Editorial Policy – Guest Posts are welcome, by submitting a guest post to AcceGen you are agree to the AcceGen Guest Post Agreement – Any concerns please contact marketing@accegen.com
